Title : Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.

Pub. Date : 2009 Feb

PMID : 19017755






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patient was treated with sunitinib, a potent tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, RET, c-KIT, and FLT-3 receptors. Sunitinib ret proto-oncogene Homo sapiens